Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application
      • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application
      • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
    October 01, 2022

    Vivos September Update

    I am pleased to provide a monthly update on our progress. I am responding to the feedback that the community appreciates the press releases, but would like more frequent updates. 

     

    FDA Pre-Submission IDE process:

     

    Our next meeting with the FDA is scheduled for October 17. We submitted our draft of the new animal test plan for VX-2 tumors in rabbits at Johns Hopkins University for FDA comments. Since RadioGel™ delivers a large dose with a small amount of activity it was necessary to fly a member of our team to JHU to determine if their PET and dose calibrators have adequate sensitivity to address the FDA expectations.

     

    Intellectual Property:

     

    As previously mentioned in our press release, we filed a hydrogel utility patent in the USA and PCT based on the last eighteen months of development work to optimize our hydrogel component. We now have much stronger patent protection than the previous coverage from licensing the original Battelle technology.

     

    Securing Component Production:

     

    Qualifying alternate suppliers is part of our strategic approach of risk identification and mitigation to prevent any possible future interruption to our product supply chain.

     

    SciPoly produced three validation lots of polymer, which are currently being tested to confirm that they meet our specifications. They will become our preferred supplier with two back-up suppliers.

     

    Our yttrium-90 is supplied by Eckert and Ziegler. We have initiated discussion for them to process their own Y-90 to supply our particles. If successful, that qualification will take many months. We would maintain our current supplier and have two particle production locations.

    "As previously mentioned in a press release we filed a hydrogel utility patent in the USA and PCT based on the last eighteen months of development work to optimize our hydrogel component. We now have much stronger patent protection than the previous coverage from licensing the original Battelle technology."

    (Mike Korenko, Sc.D • CEO • President – October 1, 2022)

    Continuous Improvement of Material Flow:

     

    Every year we examine the demographics of our patient therapies and production runs to determine if we can improve our product flow and reduce material cost. 

     

    To streamline the production process, we decided to standardize the unit volumes of hydrogel and particle solutions. We also decided to pre-mix both components prior to shipping into a standard size vial. We currently send both components to the therapists to be combined at the clinics. We performed testing to confirm that the radiation effect of premixing does not impact its rheology properties. This Important improvement will reduce the shipping costs, eliminate the mixing time at the regional clinics, reduce the low probability of contamination during mixing, and simplify the regional clinic training. 

     

    We will demonstrate these improvements on our next IsoPet™ therapy scheduled in October.

     

    Marketing:

     

    We have spent significant resources on developing a great medical technology. We are now focused on bringing awareness of IsoPet® to more veterinarians and with pet patients to increase the number of patients that we treat. 

     

    We have just augmented our current marketing effort by creating a Marketing Steering Board with veterinarians and other advisors that have germane experience. We conducted our first Board call in September and plan to expand the membership and implement their suggestions.

     

    Mike Korenko Sc. D

    President & CEO Vivos, Inc.

     

      

    CONTACT:
    Vivos Inc.
    Michael K. Korenko, Sc.D.
    President & CEO
    MKorenko@RadioGel.com

     

    tagPlaceholderTags:

    Vivos, Inc.

    Precision Radionuclide Therapy (PRnT)

    OTCQB: RDGL

    contact: info@radiogel.com


    Home Page Cover Image: 

     

    Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

     

    Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

    RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

    IsoPet® Therapy Application(s)


    Precision Radionuclide Therapy (PRnT)


    Vivos Inc.
     - (OTCQB: RDGL) Investor Relations 

    Contact

     

    Main colors
       bg-primary
       bg-primary-light
       bg-primary-dark
       bg-secondary
       bg-secondary-dark
    Template sections
       body
       top-header
       header
       content
    Footer Styles
       background
       text color
       link color
       horizontal line
    Buttons
       style 1
       style 2
       style 3
    Other elements
      social icons
      navigation color
      subnav background
    Mobile navigation
       background color
       navigation color
    Template configurations
    has-right-nav g-font
    navigation styles
    size-15 weight-400 snip-nav
    content styles
    form-white
    footer styles
    o-form color-white
    Typography
    Heading H1
    weight-600
    Heading H2
    weight-600
    Heading H3
    weight-600
    Buttons
    weight-600 is-uppercase
    Animations

    Note:
    All changes made here will be applied to your entire website.
    is-switcher admin-only

    RadioGel™ Logo

    Precision Radionuclide Therapy (PRnT)

    draggable-logo

    About | Privacy Policy | Cookie Policy | Sitemap
    © 2023 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
    Log out | Edit
    • Scroll to top